Multiple myeloma kills primarily through a cascade of organ damage driven by unchecked cancer cell growth, with disease progression accounting for roughly two-thirds of deaths in large retrospective studies.1PubMed Central. Understanding mortality in multiple myeloma: Findings of a European retrospective chart review But “disease progression” is a clinical euphemism that doesn’t tell you what actually happens inside the body. The real killers are specific complications: kidney failure, overwhelming infection, dangerously high calcium, blood that clots or bleeds when it shouldn’t, and a bone marrow so overrun with cancer cells that it can no longer do its job. How and when these complications become fatal depends on the stage of disease, the treatments used, and the individual’s overall health.
Why Disease Progression Alone Isn’t the Full Story
When doctors record “disease progression” as the cause of death for a myeloma patient, it sounds like the cancer simply grew until the body gave out. The reality is messier. In a European chart review of myeloma deaths, even among patients whose death was attributed to disease progression, 44% had other causes listed alongside it, most commonly kidney failure (59% of those cases) and infection (28%).1PubMed Central. Understanding mortality in multiple myeloma: Findings of a European retrospective chart review Death in myeloma is rarely a single event. It’s more often a collision of several failing systems at once.
The timing matters too. Earlier in the disease course, deaths are less likely to be from the myeloma itself. Among patients who died before or during their first line of treatment, only about half had disease progression as the primary cause, with kidney failure and infection each contributing in a substantial share of cases. By the fifth line of therapy, disease progression dominated as the primary cause in the vast majority of deaths.1PubMed Central. Understanding mortality in multiple myeloma: Findings of a European retrospective chart review In other words, the longer someone lives with myeloma and cycles through treatments, the more likely it is that the cancer’s relentless growth overwhelms the body. Earlier on, the complications themselves can be what tips the balance.
Kidney Failure
Kidney damage is one of the most common and dangerous complications of myeloma, and it contributes to death in a large proportion of cases. In one end-of-life study, nearly half of myeloma patients were in renal failure at the time of death.2PubMed Central. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy The kidneys are uniquely vulnerable to this cancer because of a mechanism called cast nephropathy. Myeloma cells produce enormous quantities of abnormal protein fragments known as free light chains. These flood into the bloodstream, get filtered by the kidneys, and then clump together with a protein normally present in the kidney’s tubules. The clumps physically block the tiny tubes that filter waste, causing obstruction and direct damage to kidney tissue.3PubMed Central. Paraprotein-Related Kidney Disease: Evaluation and Treatment of Myeloma Cast Nephropathy
When kidney function deteriorates severely, the body loses its ability to clear waste, balance electrolytes, and regulate fluid. This makes other complications worse: it amplifies the dangers of high calcium, impairs the clearance of drugs used in treatment, and increases the risk of fluid overload that can strain the heart. Kidney failure in myeloma is not always a slow decline. It can present suddenly, especially when a patient becomes dehydrated, takes certain medications, or when calcium spikes abruptly. In some patients, dialysis can buy time, but once kidney failure co-occurs with advanced disease progression, the prognosis deteriorates steeply.
Infection and Sepsis
Infections are the other major co-conspirator in myeloma deaths. Myeloma is, at its core, a cancer of the immune system’s antibody-producing cells. As malignant plasma cells take over the bone marrow, normal immune cell production gets crowded out. The result is a profound deficiency in the healthy antibodies that protect against bacteria, viruses, and fungi. Patients are left immunocompromised by the disease itself, and then their treatments, many of which are immunosuppressive, deepen the problem.
Sepsis, the body’s catastrophic overreaction to an infection, is the most common reason for hospital admission among myeloma patients, accounting for about one in eight admissions. Among myeloma patients who die in the hospital, over a third carry a primary diagnosis of sepsis. When myeloma patients are admitted with sepsis, their mortality rate is roughly four to five times higher than myeloma patients admitted for other reasons.4Journal of Clinical Oncology. Outcomes of sepsis in patients with multiple myeloma Pneumonia and urinary tract infections that might be manageable in a healthy person can escalate to organ failure and death in someone whose immune defenses have been hollowed out. One end-of-life study found that over a third of myeloma patients had uncontrolled sepsis at the time of death, and the vast majority had severely low white blood cell counts.2PubMed Central. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy
Infection doesn’t just complicate the disease. It is also one of the two most common therapy-related causes of death, alongside second cancers, particularly as patients undergo prolonged courses of immunosuppressive treatment.5PubMed Central. Treatment and disease-related complications in multiple myeloma: Implications for survivorship
Hypercalcemia and Bone Destruction
Myeloma is notorious for destroying bone. The cancer cells activate osteoclasts, the cells responsible for breaking down bone tissue, while suppressing the osteoblasts that build it back. This imbalance leads to bone lesions, fractures, and severe pain, but the most immediately dangerous consequence is what happens to the calcium that gets released.
When bone breaks down, calcium floods the bloodstream. Hypercalcemia is the most frequent metabolic complication of myeloma and can escalate into a life-threatening crisis.6PubMed Central. Multiple myeloma/hypercalcemia At moderately elevated levels, calcium causes confusion, extreme thirst, nausea, and constipation. At high levels, it disrupts the electrical signals that control the heart, potentially causing fatal arrhythmias. It also worsens kidney function, creating a vicious cycle: failing kidneys can’t excrete the excess calcium, which climbs higher, which damages the kidneys further. About a quarter of patients in one end-of-life cohort had hypercalcemia at the time of death.2PubMed Central. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy
Hypercalcemic crisis requires emergency treatment with intravenous fluids and drugs that slow bone breakdown. When treated promptly, it can be controlled, but when it occurs in the context of advanced, treatment-resistant disease, the window for intervention narrows. The interplay between bone destruction, kidney damage, and calcium toxicity is one of the signature lethal feedback loops in myeloma.7PubMed. An emergency medicine review: Multiple myeloma and its complications
Bone Marrow Failure
The bone marrow is where blood cells are made, and myeloma essentially hijacks it. As malignant plasma cells multiply, they physically crowd out the precursors for red blood cells, white blood cells, and platelets. The severity of the resulting anemia correlates with how extensively myeloma cells have infiltrated the marrow.8Blood. Effects of Bone Marrow Infiltration By Multiple Myeloma on Erythropoiesis Severe anemia means tissues throughout the body don’t get enough oxygen, which stresses the heart and leaves patients profoundly fatigued, breathless, and vulnerable to organ dysfunction.
Low platelet counts, or thrombocytopenia, carry their own dangers. About one in five newly diagnosed myeloma patients have thrombocytopenia, and their median overall survival is less than half that of patients with normal platelet counts. Even after accounting for other risk factors like age, genetic abnormalities, and disease stage, thrombocytopenia independently more than doubles the risk of death.9Elsevier Inc. / PubMed Central. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies Dangerously low platelets can cause uncontrolled bleeding, from nosebleeds and bruising to hemorrhagic strokes and gastrointestinal bleeds. When all three blood cell lineages are suppressed, a state called pancytopenia, the body’s reserves for fighting infection, carrying oxygen, and stopping bleeding are all depleted at once.
Blood Clots and Hyperviscosity
Myeloma creates a hypercoagulable state, meaning the blood is abnormally prone to clotting. Several mechanisms drive this, including elevated levels of inflammatory signaling molecules, excess immunoglobulin production, and defects in the body’s natural clot-dissolving system.10PubMed Central. Pulmonary embolism as the first manifestation of multiple myeloma Some myeloma treatments, particularly immunomodulatory drugs, add to this clotting risk.
Venous thromboembolism, which includes deep vein thrombosis and pulmonary embolism, occurs in about 5% of myeloma hospital admissions. The consequences are significant: hospitalized myeloma patients with a blood clot have nearly 80% higher odds of dying during that admission compared to those without one.11Blood. Venous thromboembolism in multiple myeloma: A nationwide analysis of risk factors, mortality, and disparities A massive pulmonary embolism, where a clot blocks the arteries in the lungs, can kill within minutes.
A separate but related vascular problem is hyperviscosity syndrome. In some myeloma subtypes, the abnormal protein produced by cancer cells accumulates to such high levels that the blood literally thickens. This sludgy blood doesn’t flow properly through small vessels, causing blurred vision, headaches, mucosal bleeding, and neurological problems.12Blood. IgA Pyroglobulin, Hyperviscosity Syndrome and Coagulation Abnormality in a Patient With Multiple Myeloma In severe cases, hyperviscosity can cause stroke or heart failure.13PubMed Central. Cerebral infarction in IgG multiple myeloma with hyperviscosity Plasmapheresis, a procedure that physically removes the excess protein from the blood, can provide emergency relief, but the underlying cancer must be controlled to prevent recurrence.
Cardiac Damage From Amyloid and Light Chain Deposits
Some myeloma patients develop a related condition called AL amyloidosis, where the light chain proteins produced by cancer cells misfold and deposit in organs throughout the body. The heart is one of the most dangerous sites for these deposits. When amyloid infiltrates the heart muscle, it stiffens the walls, restricting the heart’s ability to fill and pump. This restrictive cardiomyopathy leads to heart failure, abnormal heart rhythms, and sudden cardiac death.14PubMed Central. Incidence and effect of secondary cardiac amyloidosis on outcomes of patients with t(11;14) multiple myeloma
Even without forming classic amyloid fibrils, light chains can deposit directly in the heart and cause a similar pattern of restrictive cardiomyopathy. This condition, light chain deposition disease, requires specialized staining of heart tissue to diagnose and can be easily missed.15PubMed. Light chain deposition disease as a rare cause of restrictive cardiomyopathy For patients with cardiac involvement from either amyloidosis or direct light chain deposition, the heart becomes the primary threat to survival. The breathlessness, fluid retention, and rhythm disturbances from a stiff, failing heart are difficult to manage and carry a poor prognosis.
Spinal Cord Compression and Skeletal Emergencies
Myeloma’s appetite for bone creates structural weaknesses throughout the skeleton, particularly in the spine. When a vertebra weakened by myeloma collapses or when a tumor mass (plasmacytoma) grows into the spinal canal, it can compress the spinal cord. This occurs in roughly 5% of myeloma patients and constitutes a medical emergency.16PubMed Central. Spinal Cord Compression as a Consequence of Spinal Plasmacytoma in a Patient with Multiple Myeloma: A Case Report If not treated rapidly with steroids, radiation, or surgery, spinal cord compression causes permanent paralysis and loss of bladder and bowel control.
While spinal cord compression itself isn’t usually the direct cause of death, the downstream consequences can be. Paralysis leads to immobility, which dramatically raises the risk of deep vein thrombosis, pressure sores that become infected, pneumonia from impaired breathing, and a general spiral of deconditioning that hastens death. For a patient already dealing with immunocompromise and low blood counts, the loss of mobility can be the tipping point.
Treatment-Related Fatal Complications
The treatments that extend life in myeloma carry their own risks of death, and the line between dying of the disease and dying of its treatment blurs as patients move through successive therapies. The two most common therapy-related causes of death are infection and second cancers.5PubMed Central. Treatment and disease-related complications in multiple myeloma: Implications for survivorship Prolonged immunosuppression from drugs like lenalidomide, combined with the immune deficiency from the disease itself, makes patients vulnerable to infections that can be fatal even with aggressive antibiotic treatment. Second cancers, including myelodysplastic syndromes and acute leukemia, may emerge years after treatment and carry grim prognoses of their own.
Heart toxicity from specific drugs is another concern. Carfilzomib, a proteasome inhibitor widely used in relapsed myeloma, has a strong association with heart failure, hypertension, and abnormal heart rhythms.17PubMed Central. Carfilzomib-induced Cardiotoxicity: An Analysis of the FDA Adverse Event Reporting System (FAERS) For a patient whose heart may already be under strain from anemia, fluid overload, or amyloid deposits, drug-induced cardiotoxicity can push the system past its limit.
Newer immunotherapies, including CAR-T cell therapy, bring powerful new tools but also novel dangers. Cytokine release syndrome, where the activated immune cells trigger a massive inflammatory response, occurs in roughly one in five myeloma patients undergoing CAR-T therapy. A rarer but more ominous neurological side effect called immune effector cell-associated neurotoxicity syndrome occurs in about one in ten patients and is associated with more than double the odds of in-hospital death.18Blood. Incidence, outcomes and economic burden of cytokine release syndrome and immune effector cell associated neurotoxicity syndrome in patients undergoing CAR-T cell therapy for multiple myeloma Overall in-hospital mortality for CAR-T patients in that analysis was about 2%, a small number in percentage terms but a meaningful one for the patient in the bed.
Plasma Cell Leukemia
In a small but devastating fraction of cases, myeloma transforms into plasma cell leukemia, where malignant plasma cells spill out of the bone marrow and circulate freely in the blood. This can happen as a late-stage transformation of existing myeloma, or it can present as a primary diagnosis. Either way, the clinical course is aggressive, with short remissions and brief survival.19PubMed Central. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group The circulating cancer cells can infiltrate organs beyond the marrow, including the liver, spleen, and central nervous system, accelerating multi-organ failure. Plasma cell leukemia represents the most extreme form of disease progression and remains one of the most treatment-resistant variants of myeloma.
Muscle Wasting and Physical Decline
Beyond the discrete organ-threatening complications, myeloma patients face a broader erosion of physical resilience that ultimately contributes to death. Sarcopenia, the progressive loss of muscle mass and strength, is well documented in myeloma. One study found that muscle mass decreased significantly after treatment in all patients, and the effect was compounded by age in patients over 60.20PubMed Central. Sarcopenia in patients with multiple myeloma and autologous hematopoietic stem cell transplantation The causes are layered: the cancer itself drives inflammation and catabolism, chemotherapy damages healthy tissue, prolonged steroid use breaks down muscle, and reduced appetite and nausea limit nutritional intake.
This gradual wasting may not show up on death certificates, but it profoundly shapes the trajectory toward death. Patients with less muscle and physical reserve tolerate complications poorly. A bout of pneumonia that a stronger patient could fight through becomes fatal in someone already deconditioned. A fall from weakness leads to a fracture in an already fragile skeleton, triggering immobility and infection. The feedback loops between disease, treatment, and physical decline converge in the final months and weeks of life, making the body progressively less capable of weathering each new crisis.
How These Complications Converge
What makes myeloma particularly lethal is not any single complication in isolation but how they reinforce each other. High calcium damages the kidneys. Failing kidneys raise calcium higher. Bone destruction causes pain and immobility, which increases clot risk. Immunosuppression from the disease and its treatment opens the door to infections, which stress already-weakened kidneys and hearts. Anemia reduces oxygen delivery to every organ, lowering the threshold for cardiac events. Light chain deposits stiffen the heart while clogging the kidneys.
At the end of life, a typical myeloma patient is contending with several of these simultaneously. In one study of patients who died during the era of modern immunotherapy, disease progression coexisted with renal failure, sepsis, or hypercalcemia in the majority of cases, and most patients had profoundly low white blood cell counts.2PubMed Central. End-of-life management of multiple myeloma patients in the era of CD38 and immunotherapy The question “how does myeloma kill you” rarely has a single answer for any individual patient. It is almost always a combination, with one complication tipping the balance while others have been eroding the body’s reserves for months or years. Understanding these mechanisms doesn’t just satisfy curiosity; it explains why myeloma care involves not only treating the cancer but aggressively managing kidneys, bones, blood counts, infections, and heart function, because any one of those fronts failing can be the one that proves fatal.